Defective angiogenesis in CXCL12 mutant mice impairs skeletal muscle regeneration.


Journal

Skeletal muscle
ISSN: 2044-5040
Titre abrégé: Skelet Muscle
Pays: England
ID NLM: 101561193

Informations de publication

Date de publication:
18 09 2019
Historique:
received: 12 03 2019
accepted: 05 09 2019
entrez: 20 9 2019
pubmed: 20 9 2019
medline: 6 5 2020
Statut: epublish

Résumé

During muscle regeneration, the chemokine CXCL12 (SDF-1) and the synthesis of some specific heparan sulfates (HS) have been shown to be critical. CXCL12 activity has been shown to be heavily influenced by its binding to extracellular glycosaminoglycans (GAG) by modulating its presentation to its receptors and by generating haptotactic gradients. Although CXCL12 has been implicated in several phases of tissue repair, the influence of GAG binding under HS influencing conditions such as acute tissue destruction remains understudied. To investigate the role of the CXCL12/HS proteoglycan interactions in the pathophysiology of muscle regeneration, we performed two models of muscle injuries (notexin and freeze injury) in mutant CXCL12 We showed that despite normal histology of the resting muscle and normal muscle stem cell behavior in the mutant mice, endothelial cells displayed an increase in the angiogenic response in resting muscle despite the downregulated transcriptomic changes induced by the CXCL12 mutation. The regenerative capacity of the CXCL12-mutated mice was only delayed after a notexin injury, but a severe damage by freeze injury revealed a persistent defect in the muscle regeneration of CXCL12 mutant mice associated with vascular defect and fibroadipose deposition with persistent immune cell infiltration. The present study shows that CXCL12 is crucial for proper muscle regeneration. We highlight that this homing molecule could play an important role in drastic muscle injuries and that the regeneration defect could be due to an impairment of angiogenesis, associated with a long-lasting fibro-adipogenic scar.

Sections du résumé

BACKGROUND
During muscle regeneration, the chemokine CXCL12 (SDF-1) and the synthesis of some specific heparan sulfates (HS) have been shown to be critical. CXCL12 activity has been shown to be heavily influenced by its binding to extracellular glycosaminoglycans (GAG) by modulating its presentation to its receptors and by generating haptotactic gradients. Although CXCL12 has been implicated in several phases of tissue repair, the influence of GAG binding under HS influencing conditions such as acute tissue destruction remains understudied.
METHODS
To investigate the role of the CXCL12/HS proteoglycan interactions in the pathophysiology of muscle regeneration, we performed two models of muscle injuries (notexin and freeze injury) in mutant CXCL12
RESULTS
We showed that despite normal histology of the resting muscle and normal muscle stem cell behavior in the mutant mice, endothelial cells displayed an increase in the angiogenic response in resting muscle despite the downregulated transcriptomic changes induced by the CXCL12 mutation. The regenerative capacity of the CXCL12-mutated mice was only delayed after a notexin injury, but a severe damage by freeze injury revealed a persistent defect in the muscle regeneration of CXCL12 mutant mice associated with vascular defect and fibroadipose deposition with persistent immune cell infiltration.
CONCLUSION
The present study shows that CXCL12 is crucial for proper muscle regeneration. We highlight that this homing molecule could play an important role in drastic muscle injuries and that the regeneration defect could be due to an impairment of angiogenesis, associated with a long-lasting fibro-adipogenic scar.

Identifiants

pubmed: 31533830
doi: 10.1186/s13395-019-0210-5
pii: 10.1186/s13395-019-0210-5
pmc: PMC6751827
doi:

Substances chimiques

Chemokine CXCL12 0
Cxcl12 protein, mouse 0
Elapid Venoms 0
Heparan Sulfate Proteoglycans 0
notexin 37223-96-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

25

Références

Oncogene. 2016 Dec 1;35(48):6212-6222
pubmed: 27212031
PLoS One. 2008 Jul 02;3(7):e2543
pubmed: 18648536
Semin Cell Dev Biol. 2017 Dec;72:19-32
pubmed: 29127046
J Cell Sci. 2010 Sep 15;123(Pt 18):3052-60
pubmed: 20736301
J Immunol. 2014 Apr 15;192(8):3908-3914
pubmed: 24639348
Stem Cell Reports. 2017 Dec 12;9(6):2018-2033
pubmed: 29198825
Circulation. 2012 Oct 9;126(15):1882-95
pubmed: 23035208
Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3362-71
pubmed: 20181837
Am J Pathol. 2011 Feb;178(2):911-23
pubmed: 21281822
Dev Cell. 2009 Jun;16(6):810-21
pubmed: 19531352
FASEB J. 2009 Nov;23(11):3906-16
pubmed: 19667120
Adv Exp Med Biol. 2019;1147:319-344
pubmed: 31147885
Tissue Cell. 1986;18(2):153-74
pubmed: 3085281
Connect Tissue Res. 2015;56(5):392-402
pubmed: 26305158
Trends Immunol. 2007 Jul;28(7):299-307
pubmed: 17560169
Cell Stem Cell. 2018 Oct 4;23(4):530-543.e9
pubmed: 30290177
Biomaterials. 2014 May;35(15):4525-4535
pubmed: 24612919
Stem Cells Dev. 2014 Jun 15;23(12):1417-27
pubmed: 24548137
Curr Top Dev Biol. 2014;108:247-81
pubmed: 24512712
Sci Signal. 2016 Nov 01;9(452):ra107
pubmed: 27803285
Regeneration (Oxf). 2015 Oct 12;2(4):182-201
pubmed: 27499874
Circulation. 2004 May 25;109(20):2454-61
pubmed: 15148275
J Am Heart Assoc. 2017 Nov 7;6(11):
pubmed: 29114002
Cells Tissues Organs. 2004;176(1-3):67-78
pubmed: 14745236
Leukemia. 2006 Nov;20(11):1915-24
pubmed: 16900209
Circ Res. 2005 Apr 15;96(7):784-91
pubmed: 15761195
Blood. 2004 Dec 1;104(12):3472-82
pubmed: 15284120
J Cell Sci. 2004 Jan 1;117(Pt 1):73-84
pubmed: 14627628
Ther Clin Risk Manag. 2015 Sep 01;11:1337-44
pubmed: 26366086
Cell. 2006 Jan 13;124(1):175-89
pubmed: 16413490
Blood. 2006 Jan 1;107(1):111-7
pubmed: 16166582
PLoS One. 2016 Jan 25;11(1):e0147198
pubmed: 26807982
Biol Cell. 2012 Dec;104(12):722-37
pubmed: 22978573
Am J Pathol. 2008 Dec;173(6):1617-27
pubmed: 19008372
Mol Biol Cell. 2007 Apr;18(4):1397-409
pubmed: 17287398
Immunity. 2006 Dec;25(6):977-88
pubmed: 17174120
J Leukoc Biol. 2016 Jun;99(6):935-53
pubmed: 26701132

Auteurs

David Hardy (D)

Experimental Neuropathology Unit, Institut Pasteur, 75015, Paris, France.

Mylène Fefeu (M)

Experimental Neuropathology Unit, Institut Pasteur, 75015, Paris, France.

Aurore Besnard (A)

Experimental Neuropathology Unit, Institut Pasteur, 75015, Paris, France.

David Briand (D)

Experimental Neuropathology Unit, Institut Pasteur, 75015, Paris, France.

Paméla Gasse (P)

Viral Pathogenesis Unit, Institut Pasteur, 75015, Paris, France.

Fernando Arenzana-Seisdedos (F)

Viral Pathogenesis Unit, Institut Pasteur, 75015, Paris, France.

Pierre Rocheteau (P)

Experimental Neuropathology Unit, Institut Pasteur, 75015, Paris, France.
Service Hospitalo-Universitaire de Psychiatrie, Centre Hospitalier Sainte Anne, 75014, Paris, France.

Fabrice Chrétien (F)

Experimental Neuropathology Unit, Institut Pasteur, 75015, Paris, France. Fabrice.chretien@pasteur.fr.
Paris Descartes University, Sorbonne Paris Cité, 75006, Paris, France. Fabrice.chretien@pasteur.fr.
Service Hospitalo-Universitaire de Neuropathologie, Centre Hospitalier Sainte Anne, 75014, Paris, France. Fabrice.chretien@pasteur.fr.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH